China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project

Last updated: August 13, 2024
Sponsor: Peking University First Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Warts

Eczema (Atopic Dermatitis - Pediatric)

Dermatitis, Atopic

Treatment

N/A

Clinical Study ID

NCT05316805
PKU202108
  • All Genders

Study Summary

In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Patients from the medical units that has passed the data review of the NationalClinical Center for Skin and Immune Diseases (see the study sites for datacollection for details);

  2. patients diagnosed with type 2 inflammatory skin diseases (dermatitis/eczema,urticaria, pemphigoid, prurigo nodularis).

Exclusion

Exclusion Criteria:

  1. patients who fail to provide informed consent form;

  2. patients who cannot complete the questionnaire independently or under the guidanceof investigators

Study Design

Total Participants: 100000
Study Start date:
August 31, 2021
Estimated Completion Date:
December 31, 2031

Connect with a study center

  • Peking University First Hospital

    Beijing,
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.